Matthew Angel
Chief Executive Officer at Factor Bioscience, Inc.
Net worth: 116 760 $ as of 2024-03-30
Matthew Angel active positions
Companies | Position | Start | End |
---|---|---|---|
Factor Bioscience, Inc.
Factor Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Factor Bioscience, Inc. develops regenerative medicine by targeting and repairing the molecular origins of disease. It offers gene editing, cell reprogramming and nucleic-acid delivery. The company was founded by Matt Angel and Christopher Rohde in 2011 and is headquartered in Cambridge, MA. | Chief Executive Officer | 2010-12-31 | - |
Chairman | 2010-12-31 | - | |
Founder | 2010-12-31 | - | |
Exacis Biotherapeutics, Inc.
Exacis Biotherapeutics, Inc. Medical/Nursing ServicesHealth Services Part of Eterna Therapeutics, Inc., Exacis Biotherapeutics, Inc. is a development stage immuno-oncology company based in Cambridge, MA. Exacis uses its proprietary-based technologies to engineer next generation off-the-shelf NK and T cell therapies aimed at liquid and solid tumors. Exacis has an exclusive license to the Factor Bioscience technology for engineered NK and T cell products derived from iPSCs for use in oncology and holds all development and commercial rights for these investigational candidates. Exacis' approach avoids the use of DNA and viruses and instead uses a proprietary-based technology to generate iPSCs and to edit their genome to create stealthed, performance-enhanced allogeneic NK and T cell products, termed ExANK™, Exacar-NK™, and Exacar-T™ cells. The private company was founded in 2020 by Gregory Fiore, Matthew Angel, James Pan. Gregory Fiore has been the CEO since 2020. Exacis Biotherapeutics was acquired by Eterna Therapeutics, Inc. on May 02, 2023 for $49 million. | Director/Board Member | 2019-12-31 | - |
Chief Tech/Sci/R&D Officer | - | - | |
Founder | 2019-12-31 | - | |
Corporate Secretary | - | - | |
Treasurer | - | - |
Career history of Matthew Angel
Former positions of Matthew Angel
Companies | Position | Start | End |
---|---|---|---|
ETERNA THERAPEUTICS INC. | Chief Executive Officer | 2023-08-08 | 2023-12-30 |
President | 2023-08-08 | 2023-12-30 | |
ETERNA THERAPEUTICS INC. | Director/Board Member | 2022-06-06 | 2023-08-03 |
Chief Executive Officer | 2022-05-25 | 2023-08-03 | |
Corporate Officer/Principal | - | 2022-05-25 | |
President | 2022-05-25 | 2023-08-03 | |
Novellus LLC
Novellus LLC Pharmaceuticals: MajorHealth Technology Novellus LLC operates as a pharmaceutical company. The company is headquartered in Cambridge, MA. | Director/Board Member | 2013-12-31 | - |
Founder | 2013-12-31 | 2021-06-30 | |
Corporate Secretary | 2013-12-31 | 2021-06-30 |
Training of Matthew Angel
Massachusetts Institute of Technology | Doctorate Degree |
Princeton University | Undergraduate Degree |
Statistics
International
United States | 7 |
Operational
Director/Board Member | 3 |
Founder | 3 |
Chief Executive Officer | 3 |
Sectoral
Health Technology | 3 |
Finance | 2 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
ETERNA THERAPEUTICS INC. | Health Technology |
Private companies | 3 |
---|---|
Novellus LLC
Novellus LLC Pharmaceuticals: MajorHealth Technology Novellus LLC operates as a pharmaceutical company. The company is headquartered in Cambridge, MA. | Health Technology |
Factor Bioscience, Inc.
Factor Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Factor Bioscience, Inc. develops regenerative medicine by targeting and repairing the molecular origins of disease. It offers gene editing, cell reprogramming and nucleic-acid delivery. The company was founded by Matt Angel and Christopher Rohde in 2011 and is headquartered in Cambridge, MA. | Commercial Services |
Exacis Biotherapeutics, Inc.
Exacis Biotherapeutics, Inc. Medical/Nursing ServicesHealth Services Part of Eterna Therapeutics, Inc., Exacis Biotherapeutics, Inc. is a development stage immuno-oncology company based in Cambridge, MA. Exacis uses its proprietary-based technologies to engineer next generation off-the-shelf NK and T cell therapies aimed at liquid and solid tumors. Exacis has an exclusive license to the Factor Bioscience technology for engineered NK and T cell products derived from iPSCs for use in oncology and holds all development and commercial rights for these investigational candidates. Exacis' approach avoids the use of DNA and viruses and instead uses a proprietary-based technology to generate iPSCs and to edit their genome to create stealthed, performance-enhanced allogeneic NK and T cell products, termed ExANK™, Exacar-NK™, and Exacar-T™ cells. The private company was founded in 2020 by Gregory Fiore, Matthew Angel, James Pan. Gregory Fiore has been the CEO since 2020. Exacis Biotherapeutics was acquired by Eterna Therapeutics, Inc. on May 02, 2023 for $49 million. | Health Services |
- Stock Market
- Insiders
- Matthew Angel
- Experience